Fourth quarter net sales of $2.023 billion increased 4.3% and 4.9% on a constant currency1 basis Fourth quarter diluted earnings per share were $1.20; adjusted1 ...
The global joint replacement devices market, valued at US$22.50 billion in 2023, is forecasted to grow at a robust CAGR of ...
Zimmer Biomet Holdings ... a total knee implant component, and FDA’s premarket application supplement approval for the Oxford Cementless Partial Knee. These developments might have had a ...
Q4 2024 Earnings Call Transcript February 6, 2025 Zimmer Biomet Holdings, Inc. beats earnings expectations. Reported EPS is ...
Good morning, ladies and gentlemen, and welcome to the Zimmer Biomet Fourth Quarter 2024 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded today, ...
Hosted on MSN15d
Zimmer Biomet Set to Report Q4 Earnings: What's in Store?Zimmer Biomet Holdings, Inc. ZBH is scheduled to report fourth-quarter 2024 results on Feb. 6, before market open. See the Zacks Earnings Calendar to stay ahead of market-making news. In the last ...
3d
The global joint replacement devices market, valued at US$22.50 billion in 2023, is forecasted to grow at a robust CAGR of 4.8%, reaching US$23.42 ...
Zimmer Biomet's Q4 2024 revenue increased by 4.3% year-over-year. The company launched significant new products, including the Oxford Partial Cementless Knee. Zimmer Biomet anticipates 3-5% ...
Zimmer Biomet posted Q4 adjusted EPS of $2.31, surpassing estimates, with sales of $2.02B, driven by strong knee and hip product growth. The company expects FY25 adjusted EPS of $8.15-$8.35 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback